Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Assembly Biosciences ( (ASMB) ) has provided an announcement.
On March 24, 2026, Assembly Biosciences’ board compensation committee approved a new 2026 Corporate Bonus Plan, effective January 1, 2026, establishing a performance-based cash incentive structure for employees based on a mix of company-wide and individual objectives over each annual performance period. The plan, which scales bonus targets and the weighting of corporate versus individual goals by seniority level and allows payouts ranging from zero to 1.5 times target, aims to strengthen retention, align staff with strategic milestones and give the committee flexibility to adjust metrics for unforeseen events when evaluating results.
Also on March 24, 2026, the committee raised Chief Executive Officer and President Jason A. Okazaki’s bonus target from 60% to 65% of base salary for fiscal 2026 under an amendment to his employment agreement, tying his higher potential variable pay fully to corporate performance objectives. This adjustment underscores the board’s emphasis on performance-linked executive compensation and signals confidence in management’s role in achieving the company’s 2026 financial and operational goals.
The most recent analyst rating on (ASMB) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.
Spark’s Take on ASMB Stock
According to Spark, TipRanks’ AI Analyst, ASMB is a Neutral.
The score is primarily held back by weak financial performance—recurring losses, zero revenue in 2025, and ongoing cash burn—despite low leverage. Technicals are mixed but skew weak with negative momentum indicators and price below key short-to-mid-term averages. Valuation adds further caution due to negative earnings and no dividend support.
To see Spark’s full report on ASMB stock, click here.
More about Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company focused on developing therapies, with its operations structured around a corporate workforce that includes executive and non-executive employees. The company uses performance-based compensation programs to align employee and management incentives with its financial and operational objectives, reflecting a strategy to attract, retain and motivate key talent in a competitive biopharmaceutical labor market.
Average Trading Volume: 97,304
Technical Sentiment Signal: Hold
Current Market Cap: $439.4M
See more insights into ASMB stock on TipRanks’ Stock Analysis page.